Literature DB >> 12955358

Variants of the CD40 ligand gene are not associated with increased susceptibility to tuberculosis in West Africa.

Sarah J Campbell1, Pardis Sabeti, Katherine Fielding, Jackson Sillah, Boubacar Bah, Per Gustafson, Kebba Manneh, Ida Lisse, Giorgio Sirugo, Richard Bellamy, Steve Bennett, Peter Aaby, Keith P W J McAdam, Oumou Bah-Sow, Christian Lienhardt, Adrian V S Hill.   

Abstract

Evidence for linkage between tuberculosis and human chromosomal region Xq26 has previously been described. The costimulatory molecule CD40 ligand, encoded by TNFSF5 and located at Xq26.3, is a promising positional candidate. Interactions between CD40 ligand and CD40 are involved in the development of humoral- and cell-mediated immunity, as well as the activation of macrophages, which are the primary host and effector cells for Mycobacterium tuberculosis. We hypothesised that common variation within TNFSF5 might affect susceptibility to tuberculosis disease and, thus, might be responsible for the observed linkage to Xq26. Sequencing 32 chromosomes from a Gambian population identified nine common polymorphisms within the coding, 3' and 5' regulatory sequences of the gene. Six single nucleotide polymorphisms (SNPs) and a 3' microsatellite were genotyped in 121 tuberculosis patients and their available parents. No association with tuberculosis was detected for these variants using a transmission disequilibrium test, although one SNP at -726 showed some evidence of association in males. This finding, however, did not replicate in a separate case control study of over 1,200 West African individuals. We conclude that common genetic variation in TNFSF5 is not likely to affect tuberculosis susceptibility in West Africa and the linkage observed in this region is not due to variation in TNFSF5.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12955358     DOI: 10.1007/s00251-003-0602-9

Source DB:  PubMed          Journal:  Immunogenetics        ISSN: 0093-7711            Impact factor:   2.846


  23 in total

1.  GOLD--graphical overview of linkage disequilibrium.

Authors:  G R Abecasis; W O Cookson
Journal:  Bioinformatics       Date:  2000-02       Impact factor: 6.937

Review 2.  Immune regulation by CD40-CD40-l interactions - 2; Y2K update.

Authors:  C van Kooten
Journal:  Front Biosci       Date:  2000-11-01

3.  Investigation of environmental and host-related risk factors for tuberculosis in Africa. I. Methodological aspects of a combined design.

Authors:  C Lienhardt; S Bennett; G Del Prete; O Bah-Sow; M Newport; P Gustafson; K Manneh; V Gomes; A Hill; K McAdam
Journal:  Am J Epidemiol       Date:  2002-06-01       Impact factor: 4.897

4.  Parametric and nonparametric linkage analysis: a unified multipoint approach.

Authors:  L Kruglyak; M J Daly; M P Reeve-Daly; E S Lander
Journal:  Am J Hum Genet       Date:  1996-06       Impact factor: 11.025

5.  Variations in the NRAMP1 gene and susceptibility to tuberculosis in West Africans.

Authors:  R Bellamy; C Ruwende; T Corrah; K P McAdam; H C Whittle; A V Hill
Journal:  N Engl J Med       Date:  1998-03-05       Impact factor: 91.245

6.  In situ expression of B7 and CD40 costimulatory molecules by normal human lung macrophages and epithelioid cells in tuberculoid granulomas.

Authors:  P Soler; V Boussaud; J Moreau; A Bergeron; P Bonnette; A J Hance; A Tazi
Journal:  Clin Exp Immunol       Date:  1999-05       Impact factor: 4.330

7.  Regulation of CD40 and CD40 ligand by the AT-hook transcription factor AKNA.

Authors:  A Siddiqa; J C Sims-Mourtada; L Guzman-Rojas; R Rangel; C Guret; V Madrid-Marina; Y Sun; H Martinez-Valdez
Journal:  Nature       Date:  2001-03-15       Impact factor: 49.962

8.  Depressed CD40 ligand expression contributes to reduced gamma interferon production in human tuberculosis.

Authors:  B Samten; E K Thomas; J Gong; P F Barnes
Journal:  Infect Immun       Date:  2000-05       Impact factor: 3.441

9.  Human leukocyte antigen (HLA)-linked control of susceptibility to pulmonary tuberculosis and association with HLA-DR types.

Authors:  S P Singh; N K Mehra; H B Dingley; J N Pande; M C Vaidya
Journal:  J Infect Dis       Date:  1983-10       Impact factor: 5.226

10.  Structural organization of the gene for CD40 ligand: molecular analysis for diagnosis of X-linked hyper-IgM syndrome.

Authors:  M Shimadzu; H Nunoi; H Terasaki; R Ninomiya; M Iwata; S Kanegasaka; I Matsuda
Journal:  Biochim Biophys Acta       Date:  1995-01-02
View more
  5 in total

1.  Polymorphism of X-linked CD40 ligand gene associated with pulmonary tuberculosis in the Han Chinese population.

Authors:  C-Y Hu; X-A Zhang; C G Meyer; T Thye; W Liu; W-C Cao
Journal:  Genes Immun       Date:  2015-06-04       Impact factor: 2.676

2.  Hyper-immunoglobulin M syndrome caused by a mutation in the promotor for CD40L.

Authors:  Erna Van Hoeyveld; Ping-Xia Zhang; Kris De Boeck; Ramsay Fuleihan; Xavier Bossuyt
Journal:  Immunology       Date:  2007-01-17       Impact factor: 7.397

3.  Mapping of a novel susceptibility locus suggests a role for MC3R and CTSZ in human tuberculosis.

Authors:  Graham S Cooke; Sarah J Campbell; Steve Bennett; Christian Lienhardt; Keith P W J McAdam; Giorgio Sirugo; Oumou Sow; Per Gustafson; Frank Mwangulu; Paul van Helden; Paul Fine; Eileen G Hoal; Adrian V S Hill
Journal:  Am J Respir Crit Care Med       Date:  2008-04-17       Impact factor: 21.405

Review 4.  Genetic studies of African populations: an overview on disease susceptibility and response to vaccines and therapeutics.

Authors:  Giorgio Sirugo; Branwen J Hennig; Adebowale A Adeyemo; Alice Matimba; Melanie J Newport; Muntaser E Ibrahim; Kelli K Ryckman; Alessandra Tacconelli; Renato Mariani-Costantini; Giuseppe Novelli; Himla Soodyall; Charles N Rotimi; Raj S Ramesar; Sarah A Tishkoff; Scott M Williams
Journal:  Hum Genet       Date:  2008-05-30       Impact factor: 4.132

Review 5.  The X chromosome and sex-specific effects in infectious disease susceptibility.

Authors:  Haiko Schurz; Muneeb Salie; Gerard Tromp; Eileen G Hoal; Craig J Kinnear; Marlo Möller
Journal:  Hum Genomics       Date:  2019-01-08       Impact factor: 4.639

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.